 | • レポートコード：B-MOR-05098 • 出版社/出版日：Mordor Intelligence / 2018年4月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、バイオシミュレーションの世界市場について調べ、バイオシミュレーションの世界規模、市場動向、市場環境、用途別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・バイオシミュレーションの世界市場インサイト ・バイオシミュレーションの世界市場環境 ・バイオシミュレーションの世界市場動向 ・バイオシミュレーションの世界市場規模 ・バイオシミュレーションの世界市場規模：用途別 ・バイオシミュレーションの世界市場：地域別市場規模・分析 ・バイオシミュレーションの北米市場規模・予測 ・バイオシミュレーションのアメリカ市場規模・予測 ・バイオシミュレーションのヨーロッパ市場規模・予測 ・バイオシミュレーションのアジア市場規模・予測 ・バイオシミュレーションの日本市場規模・予測 ・バイオシミュレーションの中国市場規模・予測 ・バイオシミュレーションのインド市場規模・予測 ・バイオシミュレーションの韓国市場規模・予測 ・関連企業情報・競争状況 |
The biosimulation market is expected to witness a CAGR of 15.9% during the forecast period. North America dominates the global biosimulation market and is expected to grow at a CAGR over the forecast period.
Need for Low Drug Discovery and Development Costs
The development of new drugs require a huge amount of research and resources. Drug discovery involves enormous investment, and the failure of drug molecule in the later phase results in wastage of effort and cost. Hence, there was a necessity to develop a tool that will outlay the future drug molecule, during the discovery phase. Biosimulation not only helps in predicting the chances of failure of a drug in the development process, but also reduces the cost of any other possible failures by shrinking the set of clinical experiments. This is the major reason that drives the growth of the global biosimulation market. The need for low drug discovery and less development cost is expected to drive this market with a high growth rate in future.
The other factors supporting the growth of the market is the increased accuracy of prediction before an actual trial and increasing healthcare expenditure along with technological advancements in the field of biosimulation.
Shortage of Trained Professionals
Professionals working in the biosimulation market have to possess comprehensive knowledge about the software and science involved in the drug development. Hence the pharmaceutical industry is lacking qualified experts working in this field, and they are looking forward to train their employees, which may consume time and resources. Therefore, the shortage of trained professionals is a limiting factor for the biosimulation market.
In spite of the scope for growth, there are some other factors restraining the global market for biosimulation, which includes lack of awareness among healthcare professionals and of standardized processes.
North America Dominates the Market
North America is anticipated to dominate the global biosimulation market followed by Europe. A large market share of this geographical segment is attributed to factors, such as, growth in the biotechnology and pharmaceutical industry, a large number of ongoing drug development processes, and increasing R&D expenditure by pharmaceutical and biotechnology companies. The Asia Pacific region is also an emerging market where growth is being driven by an increase in the number of CROs.
Key Developments in the Market
• July 2017: EQT Partners Inc. acquired Certara, which is a continuation of the convergence between healthcare and technology, as the industry further adopts biosimulation to advance drug development
Major Players: ACCELRYS, DASSAULT SYSTÈMES, ARCHIMEDES, CHEMICAL COMPUTING GROUP, CERTARA, COMPUGEN, GENEDATA, LEADSCOPE, RHENOVIA PHARMA AND IN SILICO BIOSCIENCES INC.,amongst others.
Reasons to Purchase this Report
• Current and future global biosimulation market outlook in the developed and emerging markets
• Various perspectives of the market, with the help of Porter’s five forces analysis
• The segment expected to dominate the market
• The region expected to witness the fastest growth rate during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Need for Low Drug Discovery and Development Costs
6.1.2 Need for Advanced Biosimulation Tools
6.1.3 Failure of Clinical Trials
6.1.4 Increased Spending On Healthcare Due To Rise in Per Capita Income
6.1.5 Rise in the Level of Accuracy of Prediction before Actual Trial
6.2 Market Restraints
6.2.1 Lack of Awareness among Healthcare Professionals
6.2.2 Lack of Standardized Process
6.2.3 Shortfall of Skilled Personnel to Handle the Software
6.3 Opportunities
6.4 Key challenges
7. Market Segmentation
7.1 By Application
7.1.1 Drug Discovery
7.1.1.1 Lead Optimization
7.1.1.2 Lead Validation
7.1.1.3 Target Identification
7.1.1.4 Target Validation
7.1.2 Drug Development
7.1.2.1 Pre-Clinical Testing
7.1.2.2 Clinical Trials
7.1.3 Others
7.2 By Geography
7.2.1 North America
7.2.1.1 United States
7.2.1.2 Canada
7.2.1.3 Mexico
7.2.2 Europe
7.2.2.1 France
7.2.2.2 Germany
7.2.2.3 United Kingdom
7.2.2.4 Italy
7.2.2.5 Spain
7.2.2.6 Rest of Europe
7.2.3 Asia-Pacific
7.2.3.1 China
7.2.3.2 Japan
7.2.3.3 India
7.2.3.4 Australia & New Zealand
7.2.3.5 South Korea
7.2.3.6 Rest of Asia-Pacific
7.2.4 Middle East & Africa
7.2.4.1 GCC
7.2.4.2 South Africa
7.2.4.3 Rest of the Middle East & Africa
7.2.5 South America
7.2.5.1 Brazil
7.2.5.2 Argentina
7.2.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Rhenovia Pharma
9.2 Accelrys
9.3 Certara
9.4 Genedata
9.5 Leadscope
9.6 Compugen
9.7 Archimedes
9.8 Simulations Plus, Inc.
9.9 Schrodinger Inc.
9.10 Insilico BioTechnology
9.11 List Not Exhaustive
10. Future of the Market